Found: 14
Select item for more details and to access through your institution.
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00871-1
- By:
- Publication type:
- Article
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.
- Published in:
- Frontiers of Medicine, 2023, v. 17, n. 4, p. 699, doi. 10.1007/s11684-022-0972-8
- By:
- Publication type:
- Article
Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.880108
- By:
- Publication type:
- Article
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 3, p. 457, doi. 10.1111/bjh.14570
- By:
- Publication type:
- Article
The cXcr4-sTaT3-il-10 Pathway controls the immunoregulatory Function of chronic lymphocytic leukemia and is Modulated by lenalidomide.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2017.01773
- By:
- Publication type:
- Article
Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2017.01937
- By:
- Publication type:
- Article
Ab initio spillover compensation in mass cytometry data.
- Published in:
- Cytometry. Part A, 2021, v. 99, n. 9, p. 899, doi. 10.1002/cyto.a.24298
- By:
- Publication type:
- Article
THE IMPORTANCE OF CUTANEOUS SILENT PERIOD IN UREMIC POLYNEUROPATHY.
- Published in:
- Nobel Medicus Journal, 2011, v. 7, n. 3, p. 89
- By:
- Publication type:
- Article
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00830-w
- By:
- Publication type:
- Article
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00830-w
- By:
- Publication type:
- Article
Extended live-cell barcoding approach for multiplexed mass cytometry.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-91816-w
- By:
- Publication type:
- Article
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01476-8
- By:
- Publication type:
- Article